MX2020008180A - Anticuerpos activables y métodos para elaborarlos y usarlos. - Google Patents
Anticuerpos activables y métodos para elaborarlos y usarlos.Info
- Publication number
- MX2020008180A MX2020008180A MX2020008180A MX2020008180A MX2020008180A MX 2020008180 A MX2020008180 A MX 2020008180A MX 2020008180 A MX2020008180 A MX 2020008180A MX 2020008180 A MX2020008180 A MX 2020008180A MX 2020008180 A MX2020008180 A MX 2020008180A
- Authority
- MX
- Mexico
- Prior art keywords
- making
- methods
- activatable antibodies
- activatable
- binding polypeptides
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000013598 vector Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En la presente se proporcionan bibliotecas que contienen polinucleótidos sintéticos que codifican polipéptidos de unión activables. Se proporcionan además en la presente polipéptidos de unión activables y bibliotecas de polipéptidos que contienen tales polipéptidos de unión activables. Se proporcionan también en la presente vectores, bibliotecas de vectores, células, kits y métodos para elaborar y usar las bibliotecas de polipéptidos activables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/075065 WO2019148445A1 (en) | 2018-02-02 | 2018-02-02 | Precision/context-dependent activatable antibodies, and methods of making and using the same |
PCT/CN2019/074581 WO2019149282A1 (en) | 2018-02-02 | 2019-02-02 | Activatable antibodies and methods of making and using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008180A true MX2020008180A (es) | 2020-10-19 |
Family
ID=67476415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008180A MX2020008180A (es) | 2018-02-02 | 2019-02-02 | Anticuerpos activables y métodos para elaborarlos y usarlos. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20190241886A1 (es) |
EP (1) | EP3746461A4 (es) |
JP (2) | JP2021512122A (es) |
KR (1) | KR20200128011A (es) |
CN (1) | CN112771066A (es) |
AU (2) | AU2019214189B2 (es) |
BR (1) | BR112020015380A2 (es) |
CA (1) | CA3090027A1 (es) |
IL (1) | IL276285A (es) |
MX (1) | MX2020008180A (es) |
SG (1) | SG11202007166XA (es) |
WO (2) | WO2019148445A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
WO2019204564A1 (en) | 2018-04-18 | 2019-10-24 | Exelixis, Inc. | Anti-ror antibody constructs |
WO2021226883A1 (en) * | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer submission of sequence listing on ascii text file |
WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
EP4323001A1 (en) * | 2021-04-11 | 2024-02-21 | Adagene Inc. | Combination therapies for treating cancer |
WO2023168547A1 (en) * | 2022-03-07 | 2023-09-14 | Adagene Pte. Ltd. | Anti-cd137 antibodies and methods of making and using the same |
WO2023193239A1 (en) * | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
US20240262923A1 (en) | 2022-12-21 | 2024-08-08 | Genzyme Corporation | Anti-pd-1×4-1bb binding proteins |
WO2024170773A1 (en) | 2023-02-16 | 2024-08-22 | Sanofi | Cd40-binding proteins |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
EP1024191B8 (en) | 1991-12-02 | 2008-11-05 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US7138500B1 (en) | 1993-05-07 | 2006-11-21 | Immunex Corporation | Antibodies to human 4-1BB |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
DK0766745T3 (da) | 1995-04-08 | 2002-11-25 | Lg Chemical Ltd | Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
KR20000034847A (ko) | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
EA006972B1 (ru) | 1998-12-23 | 2006-06-30 | Пфайзер Инк. | Моноклональное антитело человека к ctla-4 и способы его применения |
US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
CA2385347C (en) | 1999-10-04 | 2009-12-15 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
JP4200627B2 (ja) | 2000-03-01 | 2008-12-24 | 味の素株式会社 | 変異型チロシンリプレッサー遺伝子とその利用 |
DZ3494A1 (fr) | 2001-01-05 | 2002-07-11 | Pfizer | Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline |
KR20030068205A (ko) | 2001-01-09 | 2003-08-19 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법 |
DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
PT1446162E (pt) | 2001-08-17 | 2009-01-27 | Coley Pharm Gmbh | Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
WO2003074678A2 (en) * | 2002-03-01 | 2003-09-12 | Dyax Corp. | Modular recombinatorial display libraries |
SI1517921T1 (sl) | 2002-06-28 | 2006-10-31 | Domantis Ltd | Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo |
WO2004010947A2 (en) | 2002-07-30 | 2004-02-05 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
ATE540978T1 (de) | 2002-10-17 | 2012-01-15 | Genmab As | Humane monoklonale antikörper gegen cd20 |
ES2633311T3 (es) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
AR046094A1 (es) | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
PL2380911T3 (pl) | 2003-11-05 | 2018-10-31 | Roche Glycart Ag | Cząsteczki wiążące antygen o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US20070253961A1 (en) | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
US20080152655A1 (en) | 2004-09-08 | 2008-06-26 | The Ohio State University Research Foundation | Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies |
US20060153808A1 (en) | 2004-11-17 | 2006-07-13 | Board Of Regents, The Universtiy Of Texas System | Cancer immunotherapy incorporating p53 |
DE102004063494A1 (de) | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
WO2006088447A1 (en) | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
CA2610661A1 (en) | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
EP2395024B1 (en) | 2005-08-26 | 2018-12-19 | Roche Glycart AG | Modified antigen binding molecules with altered cell signaling activity |
CN1294146C (zh) | 2005-10-17 | 2007-01-10 | 山东大学 | 与t细胞表面共刺激分子cd137结合的多肽及其应用 |
US8324194B2 (en) | 2005-11-22 | 2012-12-04 | Incyte Corporation | Combination therapy for the treatment of cancer |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
ES2527297T3 (es) | 2007-07-31 | 2015-01-22 | Regeneron Pharmaceuticals, Inc. | Anticuerpos humanos para CD20 humano y método para utilizar los mismos |
CA2696460A1 (en) | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
AU2013202755B2 (en) | 2007-08-22 | 2016-05-12 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
ES2336873B1 (es) | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
MX2010006466A (es) | 2007-12-14 | 2010-09-28 | Bristol Myers Squibb Co | Moleculas de union al receptor ox40 de humano. |
WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
AU2010203353B2 (en) | 2009-01-12 | 2016-06-16 | Cytomx Therapeutics, Inc | Modified antibody compositions, methods of making and using thereof |
WO2010132389A2 (en) | 2009-05-14 | 2010-11-18 | University Of Maryland, Baltimore | Methods for treating cancers and diseases associated with 4-1bb (cd137) expression |
US9193791B2 (en) * | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
ES2699648T3 (es) | 2010-09-09 | 2019-02-12 | Pfizer | Moléculas de unión a 4-1BB |
JP2014506116A (ja) | 2010-11-12 | 2014-03-13 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Il−2部分とポリマーとのコンジュゲート |
PE20150643A1 (es) | 2012-06-22 | 2015-05-29 | Cytomx Therapeutics Inc | Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos |
CN105247050B (zh) | 2013-03-14 | 2020-06-16 | 天演药业 | 用于文库构建、亲和力结合剂筛选和其表达的整合系统 |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
EP3049111A2 (en) * | 2013-09-25 | 2016-08-03 | Cytomx Therapeutics Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
KR20160089532A (ko) | 2013-12-17 | 2016-07-27 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법 |
EP3082839A4 (en) | 2013-12-20 | 2017-08-09 | National University of Singapore | Differentiation therapy with cd137 ligand agonists |
DK3134123T3 (da) | 2014-02-21 | 2021-04-06 | Nektar Therapeutics India Pvt Ltd | Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof |
WO2015156268A1 (ja) | 2014-04-07 | 2015-10-15 | 中外製薬株式会社 | 免疫活性化抗原結合分子 |
BR112017001579A2 (pt) * | 2014-07-25 | 2017-11-21 | Cytomx Therapeutics Inc | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
US10689423B2 (en) | 2015-01-13 | 2020-06-23 | City Of Hope | CTLA4-binding protein peptide-linker masks |
JP6917902B2 (ja) | 2015-02-13 | 2021-08-11 | ソレント・セラピューティクス・インコーポレイテッド | Ctla4に結合する抗体医薬 |
KR20180016972A (ko) | 2015-02-22 | 2018-02-20 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd137에 결합하는 항체 치료제 |
MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
EA201792414A1 (ru) | 2015-05-04 | 2018-06-29 | Сайтомкс Терапьютикс, Инк. | Антитела против cd166, активируемые антитела против cd166 и способы их применения |
AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
BR112017024770A2 (pt) | 2015-05-21 | 2018-07-31 | Alligator Bioscience Ab | polipeptídeos inovadores |
US20160362469A1 (en) * | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
CA2986604A1 (en) * | 2015-06-26 | 2016-12-29 | University Of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
KR20180040138A (ko) * | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
DK3354661T3 (da) | 2015-09-22 | 2020-07-06 | Dingfu Biotarget Co Ltd | Fuldstændigt humant antistof mod human CD137 og anvendelse deraf |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
EP4374926A3 (en) | 2015-12-15 | 2024-08-07 | OncoC4, Inc. | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
EP3394107A1 (en) | 2015-12-22 | 2018-10-31 | AbbVie Stemcentrx LLC | Novel anti-tnfsf9 antibodies and methods of use |
WO2017140826A1 (en) | 2016-02-18 | 2017-08-24 | Institut Gustave Roussy | Methods and kits for predicting the sensitivity of a subject to immunotherapy |
CA3014466A1 (en) | 2016-03-03 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
US10875921B2 (en) | 2016-05-27 | 2020-12-29 | Abbvie Biotherapeutics Inc. | Anti-4-1BB antibodies and their uses |
EA201990293A1 (ru) | 2016-07-14 | 2019-07-31 | Генмаб А/С | Мультиспецифичные антитела против cd40 и cd137 |
CN114456269A (zh) | 2016-09-21 | 2022-05-10 | 基石药业(苏州)有限公司 | 一种新的pd-1单克隆抗体 |
GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
AU2018206015B2 (en) | 2017-01-06 | 2019-05-30 | Eutilex Co., Ltd. | Anti-human 4-1 BB antibodies and use thereof |
MX2019012223A (es) | 2017-04-13 | 2019-12-09 | Agenus Inc | Anticuerpos anti-cd137 y metodos de uso de los mismos. |
KR20180119135A (ko) | 2017-04-24 | 2018-11-01 | 주식회사 제넥신 | 4-1bbl 변이체 및 이를 포함하는 융합 단백질 |
KR20200002889A (ko) | 2017-05-02 | 2020-01-08 | 엘리게이터 바이오사이언스 에이비 | Ox40 및 ctla-4에 대한 이중특이적 항체 |
EP3625255A4 (en) | 2017-05-19 | 2021-02-24 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL MONOCLONAL ANTIBODIES AGAINST CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) |
EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
IL272696B1 (en) | 2017-08-21 | 2024-09-01 | Adagene Inc | Dynamic human heavy chain antibody libraries |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
SG11202001549UA (en) | 2017-08-21 | 2020-03-30 | Adagene Inc | Dynamic human antibody light chain libraries |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
WO2019104716A1 (en) | 2017-12-01 | 2019-06-06 | Adagene Inc. | Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
CA3139968A1 (en) | 2019-06-05 | 2020-12-10 | Peter Peizhi Luo | Anti-cd137l antibodies and methods of using same |
WO2021228178A1 (en) | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer |
AU2021297240A1 (en) | 2020-06-23 | 2023-01-19 | Adagene Pte. Ltd. | Combination therapy comprising anti-CD137 antibodies |
-
2018
- 2018-02-02 WO PCT/CN2018/075065 patent/WO2019148445A1/en active Application Filing
-
2019
- 2019-02-01 US US16/265,851 patent/US20190241886A1/en not_active Abandoned
- 2019-02-02 SG SG11202007166XA patent/SG11202007166XA/en unknown
- 2019-02-02 AU AU2019214189A patent/AU2019214189B2/en active Active
- 2019-02-02 WO PCT/CN2019/074581 patent/WO2019149282A1/en unknown
- 2019-02-02 BR BR112020015380-0A patent/BR112020015380A2/pt unknown
- 2019-02-02 CN CN201980021653.9A patent/CN112771066A/zh active Pending
- 2019-02-02 JP JP2020541957A patent/JP2021512122A/ja active Pending
- 2019-02-02 CA CA3090027A patent/CA3090027A1/en active Pending
- 2019-02-02 KR KR1020207024940A patent/KR20200128011A/ko unknown
- 2019-02-02 MX MX2020008180A patent/MX2020008180A/es unknown
- 2019-02-02 US US16/966,848 patent/US11952681B2/en active Active
- 2019-02-02 EP EP19747798.7A patent/EP3746461A4/en active Pending
-
2020
- 2020-07-26 IL IL276285A patent/IL276285A/en unknown
-
2023
- 2023-01-11 US US18/153,221 patent/US20240150749A1/en active Pending
- 2023-06-19 JP JP2023099859A patent/JP2023134458A/ja active Pending
-
2024
- 2024-09-11 AU AU2024219607A patent/AU2024219607A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240150749A1 (en) | 2024-05-09 |
SG11202007166XA (en) | 2020-08-28 |
AU2024219607A1 (en) | 2024-10-03 |
CN112771066A (zh) | 2021-05-07 |
KR20200128011A (ko) | 2020-11-11 |
BR112020015380A2 (pt) | 2020-12-22 |
JP2023134458A (ja) | 2023-09-27 |
AU2019214189A1 (en) | 2020-09-17 |
US11952681B2 (en) | 2024-04-09 |
EP3746461A1 (en) | 2020-12-09 |
IL276285A (en) | 2020-09-30 |
WO2019149282A1 (en) | 2019-08-08 |
JP2021512122A (ja) | 2021-05-13 |
EP3746461A4 (en) | 2021-11-17 |
AU2019214189B2 (en) | 2024-06-27 |
CA3090027A1 (en) | 2019-08-08 |
US20190241886A1 (en) | 2019-08-08 |
WO2019148445A1 (en) | 2019-08-08 |
US20210207126A1 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008180A (es) | Anticuerpos activables y métodos para elaborarlos y usarlos. | |
MX2021015452A (es) | Proteinas de fusion flt3l-fc y metodos de uso. | |
MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
PH12020551391A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
PH12020550408A1 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
PH12020551997A1 (en) | Psma binding agents and uses thereof | |
CR20220025A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos | |
PE20210844A1 (es) | Contorsbodies 2 + biespecificos | |
TN2018000325A1 (en) | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123. | |
EP4273233A3 (en) | Mr1 restricted t cell receptors for cancer immunotherapy | |
EP3773676A4 (en) | PROTEINS THAT BIND NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS | |
MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
MX2020001791A (es) | Modificacion de celulas t. | |
MX2021000263A (es) | Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma. | |
MX2022009674A (es) | Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa. | |
MX2022014938A (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas. | |
MX2022007288A (es) | Agentes de union a ilt3 y metodos de uso de los mismos. | |
MX2023001256A (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos. | |
MX2023009615A (es) | Moleculas de union anti-cd123 y usos de estas. | |
GB2596001A8 (en) | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class 1-like protein (OMCP) and tumor-specific binding partner | |
MX2022012062A (es) | Receptores de linfocitos t. | |
MX2021002125A (es) | Receptores de celulas t restringidos a mr1 para inmunoterapia contra el cancer. | |
CR20240139A (es) | Anticuerpos del receptor antitransferrina y usos de los mismos | |
MX2022011320A (es) | Materiales y métodos para la unión de lectina tipo ig de unión a ácido siálico. |